477220-33-0

Basic information

• Product Name: (S)-4-(Phenylmethyl)-2-piperazineethanol
• Synonyms: (s)-4-(phenylmethyl)-2-piperazineethanol;2-((S)-4-benzylpiperazin-2-yl)ethanol;2-[(2S)-4-benzylpiperazin-2-yl]ethan-1-ol;(S)-2-(4-benzylpiperazin-2-yl)ethanol-2HCl;(S)-2-(4-benzylpiperazin-2-yl)ethanol
• CAS NO: 477220-33-0
• Molecular Formula: C₁₃H₂₀N₂O
• Molecular Weight: 220.31
• Mol File: 477220-33-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 366.7 °C at 760 mmHg
• Flash Point: 175.6 °C
• Appearance: /
• Density: 1.064 g/cm³
• Vapor Pressure: 5.04E-06mmHg at 25°C
• Refractive Index: 1.544
• CAS DataBase Reference: (S)-4-(Phenylmethyl)-2-piperazineethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(Phenylmethyl)-2-piperazineethanol(477220-33-0)
• EPA Substance Registry System: (S)-4-(Phenylmethyl)-2-piperazineethanol(477220-33-0)

Safety Data

• Hazardous Substances Data: 477220-33-0(Hazardous Substances Data)

Usage

General Description

(S)-4-(Phenylmethyl)-2-piperazineethanol is a chemical compound that belongs to the family of piperazine derivatives. It is a chiral molecule with a specific stereochemistry, denoted by the (S)- in its name. (S)-4-(Phenylmethyl)-2-piperazineethanol has a phenylmethyl group and a piperazine ring, as well as an ethanol group, which gives it its alcohol functionality. It may have potential applications in medicinal chemistry, as piperazine derivatives are known for their pharmacological properties, and the presence of an alcohol group can make it suitable for derivatization and modification to create new drug candidates. The compound's specific stereochemistry may also influence its interactions with biological targets, making it a potential lead compound for drug development.

InChI:InChI=1/C13H20N2O/c16-9-6-13-11-15(8-7-14-13)10-12-4-2-1-3-5-12/h1-5,13-14,16H,6-11H2/t13-/m0/s1

Upstream product

• 612506-99-7 (S)-(4-benzyl-3,6-dioxopiperazin-2-yl) acetic acid methyl ester 
• 321918-75-6 benzyl (3S)-4-[benzyl-(2-ethoxy-2-oxoethyl)amino]-3-(tert-butoxycarbonylamino)-4-oxobutanoate 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 252873-54-4 benzyl 2-[(2S)-4-benzyl-3,6-dioxopiperazin-2-yl]acetate 

Downstream Products

• 169447-92-1 tert-butyl (2S)-4-benzyl-2-(2-hydroxyethyl)piperazine-1-carboxylate 
• 660862-47-5 (S)-2-(piperazin-2-yl)ethan-1-ol 
• 1262892-03-4 (S)-2-[(2-carbamoyl-2-methyl-propylcarbamoyl)-methyl]-4-[2-(3-fluoro-2-methyl-benzyl)-1-phenyl-indolizine-3-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1262891-97-3 (S)-4-[2-(3-fluoro-2-methyl-benzyl)-1-phenyl-indolizine-3-carbonyl]-2-{[(tetrahydropyran-4-ylmethyl)-carbamoyl]-methyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 1262891-96-2 {(S)-1-tert-butoxycarbonyl-4-[2-(3-fluoro-2-methyl-benzyl)-1-phenyl-indolizine-3-carbonyl]-piperazin-2-yl}-acetic acid 
• 1262891-95-1 (S)-4-[2-(3-fluoro-2-methyl-benzyl)-1-phenyl-indolizine-3-carbonyl]-2-(2-oxo-ethyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1262891-94-0 2-{(S)-4-[2-(3-fluoro-2-methyl-benzyl)-1-phenyl-indolizine-3-carbonyl]-piperazin-2-yl}-N-(tetrahydropyran-4-ylmethyl)-acetamide hydrochloride 
• 1262891-93-9 (S)-4-[2-(3-fluoro-2-methyl-benzyl)-1-phenyl-indolizine-3-carbonyl]-2-(2-hydroxy-ethyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 1262891-92-8 (S)-2-[2-(tert-butyl-dimethyl-silyloxy)-ethyl]-4-[2-(3-fluoro-2-methyl-benzyl)-1-phenyl-indolizine-3-carbonyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1252648-85-3 (S)-2-(4-benzyl-1-(2-bromo-5-methylphenyl)piperazin-2-yl)ethanol 
• 169448-66-2 {(R)-1-[(S)-2-(2-Cyclopropoxy-ethyl)-4-(naphthalene-1-carbonyl)-piperazin-1-ylmethyl]-2-tritylsulfanyl-ethyl}-carbamic acid tert-butyl ester 
• 169448-13-9 {(R)-1-[(S)-2-(2-Methoxy-ethyl)-4-(naphthalene-1-carbonyl)-piperazin-1-ylmethyl]-2-tritylsulfanyl-ethyl}-carbamic acid tert-butyl ester 
• 169448-17-3 tert-butyl (2S)-2-(2-hydroxyethyl)piperazine-1-carboxylate 

Relevant articles and documents

KRAS G12C INHIBITORS

The present invention provides compounds of the formula: where R1, R2, R3, R4, R5, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.

PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES

Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or -CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, N02, CN, COR4, C(O)OR4, CONR5R6 , NR5R6, S02NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen, (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyl is unsubsituted or substituted with a phenyl; R4 is hydrogen, (C1-6 alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic, R7 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R8 and R9 are independently hydrogen, (C1-6) alkyl, or optionally substituted aromatic; Ar is optionally substituted phenyl, napthyl, monocyclic heteroaromatic or bicyclic heteroaromatic; Z1 and Z2 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR7, SR7, NO2, CN, COR7, CONR8R9, NR8R9, and optionally substituted aromatic; and all salts, solvates, optical and geometric isomers, and crystalline forms thereof. Also, described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treament of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).

2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase [1]

-